natgillin/translations-raw huggingface dataset:
For the induction treatment of inoperable locally advanced squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m2 as a 1 hour infusion followed by cisplatin 75 mg/m2 over 1 hour, on day one, followed by 5-fluorouracil as a continuous infusion at 750 mg/m2 per day for five days.
Za indukcijsko zdravljenje inoperabilnega lokalno napredovalega skvamoznoceličnega karcinoma glave in vratu (SCCHN – squamous cell carcinoma of the head and neck), je priporočeni odmerek docetaksela 75 mg/m2 v obliki enourne infuzije, ki ji sledi cisplatin 75 mg/m2, infundiran 1 uro dolgo, prvega dne, temu pa sledi 5-fluorouracil v obliki neprekinjene infuzije v odmerku 750 mg/m2 na dan pet dni.
For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m2 administered as a 30-minute to 3 hour infusion, followed by 5-fluorouracil 1000 mg/m2/day as a continuous infusion from day 1 to day 4.
Za indukcijsko zdravljenje bolnikov z lokalno napredovalim skvamoznoceličnim karcinomom glave in vratu (SCCHN) (neresektabilen, majhna verjetnost kirurške ozdravitve, namen ohranitve organa) je priporočeni odmerek docetaksela 75 mg/m2 v enourni intravenski infuziji prvi dan, ki mu sledi cisplatin 100 mg/m2 v 30-minutni do 3-urni infuziji in nato neprekinjena intravenska infuzija 5-fluorouracila 1000 mg/m2/dan od prvega do četrtega dne.
For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m2 as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m2 administered as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000 mg/m2/day as a continuous infusion from day 1 to day 4.
Za indukcijsko zdravljenje bolnikov z lokalno napredovalim (neresektabilen, majhna verjetnost kirurške ozdravitve, ohranitev organa) skvamoznoceličnim karcinomom glave in vratu (SCCHN) je priporočen odmerek docetaksela 75 mg/m2 v obliki enourne intravenske infuzije 1. dan, ki mu sledi cisplatin 100 mg/m2 v 30-minutni do 3-urni infuziji in nato stalna intravenska infuzija 5-fluorouracila 1000 mg/m2/dan od 1. do 4. dneva.
For the induction treatment of patients with locally advanced (technically unresectable, low probability of surgical cure, and aiming at organ preservation) squamous cell carcinoma of the head and neck (SCCHN), the recommended dose of docetaxel is 75 mg/m² as a 1 hour intravenous infusion on day 1, followed by cisplatin 100 mg/m² administered as a 30-minute to 3-hour infusion, followed by 5-fluorouracil 1000 mg/m²/day as a continuous infusion from day 1 to day 4.
Za indukcijsko zdravljenje bolnikov z lokalno napredovalim (neresektabilen, majhna verjetnost kirurške ozdravitve, ohranitev organa) skvamoznoceličnim karcinomom glave in vratu (SCCHN) je priporočen odmerek docetaksela 75 mg/m² v obliki enourne intravenske infuzije 1. dan, ki mu sledi cisplatin 100 mg/m² v 30-minutni do 3-urni infuziji in nato stalna intravenska infuzija 5-fluorouracila 1000 mg/m²/dan od 1. do 4. dneva.
For the inhalation you should use a mouthpiece to prevent Ventavis coming into contact with your skin.
Pri vdihavanju uporabite ustnik, da preprečite stik zdravila Ventavis s kožo.
For the initial vaccination the number of injections needed and the dose varies according to the type of female pig being treated: gilts (female pigs that have not yet had piglets) should receive one 2 ml injection three times; sows (female pigs that have had piglets before) should receive one 2 ml injection twice.
Pri začetnem cepljenju so število potrebnih injiciranj in odmerki odvisni od vrste samice, ki jo zdravimo: mladice (prašičje samice, ki še niso nikoli povrgle pujskov) morajo en 2-mililitrski odmerek prejeti trikrat, svinje (prašičje samice, ki so že povrgle pujske) pa morajo en 2-mililitrski odmerek prejeti dvakrat.
For the initiation of treatment, the pharmacy will provide a starter pack containing the medicinal product, a reclosable bottle cap adapter and 7 CE marked oral syringes appropriately sized to administer the correct dose (see section 6.5).
Za uvedbo zdravljenja bodo v lekarni izdali začetno pakiranje, ki vsebuje zdravilo, zamašek z nastavkom za brizgo in 7 peroralnih brizg z oznako CE ustreznih velikosti za odmerjanje pravilnega odmerka (glejte poglavje 6.5).
For the Initiation Pack injections, you can use the record table printed on the inside of the lid of the Initiation Pack.
Za injiciranje začetnega pakiranja lahko uporabite kartico s preglednico na notranji strani pokrova škatle začetnega pakiranja.
For the injection you will need the following:
Za injiciranje boste potrebovali:
For the intravitreal injection, a 30 G x ½ inch injection needle should be used.
Za intravitrealno injekcijo uporabite injekcijsko iglo 30 G x 12,7 mm.
For the IPD secondary endpoint, there were 35 (7 Prevenar 13: 28 Placebo) first episodes of VT-IPD, resulting in an efficacy of 75.00% (95.2% CI, 41.06-90.87; p=0.0005).
Za sekundarni opazovani dogodek IPD je bilo 35 (7 Prevenar 13 : 28 placebo) prvih epizod VT-IPD, torej je učinkovitost znašala 75,00 % (95,2 % IZ; 41,06-90,87; p = 0,0005).
For the ITT population, median PFS time by Independent Review Adjudication Committee (IRAC) review based on IMWG criteria was 15.7 weeks (95% CI: 13.0, 20.1) in the Pom + LD-Dex arm; the estimated 26-week event-free survival rate was 35.99% (±3.46%).
Za populacijo ITT je bil mediani čas PFS po pregledu Neodvisnega presojevalnega odbora (IRAC - Independent Review Adjudication Committee) na podlagi kriterijev IMWG 15,7 tednov (95 % IZ: 13,0; 20,1) v skupini POM + NO-deks; ocenjena 26-tedenska stopnja preživetja brez dogodkov je bila
For the limitations in the interpretation of a positive scan, see sections 4.4 and 5.1.
Za omejitve pri interpretaciji pozitivnega rezultata preiskave glejte poglavji 4.4 in 5.1.
For the long term treatment Vimpat tablets and syrup are available.
Za dolgotrajno zdravljenje so na voljo tablete in sirup zdravila Vimpat.
For the long term treatment with Briviact, your doctor will ask to you totake Briviact tablets or oral solution.
Za dolgotrajno zdravljenje z zdravilom Briviact vam bo zdravnik naročil, da vzamete tablete ali peroralno raztopino zdravila Briviact.
For the lyophilisate and the solvent: 3-ml vials of glass Type I closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap.
Liofilizat in vehikel: viale po 3 ml iz stekla tipa I, zaprte z zamaški iz halogenobutilne gume in zatesnjene z aluminijastimi zaporkami s šifro.
For the majority of breeds the use of ibafloxacin is contra-indicated in dogs less than 8 months of age and in giant breeds less than 18 months.
Pri večini pasem je uporaba ibafloksacina kontraindicirana za pse, mlajše od 8 mesecev in pri zelo velikih pasmah za pse, mlajše od 18 mesecev.
For the majority of breeds the use of ibafloxacin is contra-indicated in dogs less than 8 months of age, and in giant breeds less than 18 months.
Pri večini pasem je uporaba ibafloksacina kontraindicirana za pse, mlajše od 8 mesecev in pri zelo velikih pasmah za pse, mlajše od 18 mesecev.
For the majority of breeds the use of ibafloxacin is contra-indicated in dogs less than 8 months of age, and in giant breeds less than 18 months.
Pri večini pasem je uporaba ibafloksacina kontraindicirana za pse, mlajše od 8 mesecev, pri zelo velikih pasmah pa za pse, mlajše od 18 mesecev.
For the majority of breeds, the use of ibafloxacin is contra-indicated in dogs less than 8 months of age and in giant breeds less than 18 months old.
Pri večini pasem je uporaba ibafloksacina kontraindicirana za pse, mlajše od 8 mesecev, pri zelo velikih pasmah pa za pse, mlajše od 18 mesecev.
For the majority of breeds, the use of ibafloxacin is contra-indicated in dogs less than 8 months of age, and in giant breeds less than 18 months.
Pri večini pasem je uporaba ibafloksacina kontraindicirana za pse, mlajše od 8 mesecev, pri zelo velikih pasmah pa za pse, mlajše od 18 mesecev.
For the male patients taking Siklos, if your partner becomes pregnant or plans to become pregnant, your doctor will discuss with you the potential benefits and risks of continuing using Siklos.
Če ste moški bolnik, ki jemlje zdravilo Siklos, in vaša partnerica zanosi ali načrtuje nosečnost, se bo zdravnik z vami pogovoril o potencialnih koristih in tveganjih nadaljevanja zdravljenja z zdravilom Siklos.
For the management of selected adverse reactions please also refer to section 4.4. Tabulated list of adverse reactions
Za obravnavo izbranih neželenih učinkov glejte tudi poglavje 4.4. Seznam neželenih učinkov
For the management of selected adverse reactions, see section 4.4. Information about selected adverse reactions observed from the LUME-Lung 1 trial are described below.
Za obravnavo izbranih neželenih učinkov glejte poglavje 4.4. Podatki o izbranih neželenih učinkih, ki so jih opazili v preskušanju LUME-Lung 1, so opisani spodaj.
For the manufacture of Holoclar, a biopsy of 1 - 2 mm2 of undamaged limbus is required.
Za izdelavo zdravila Holoclar je treba z biopsijo odvzeti 1 – 2 mm2 nepoškodovanega limbusa.
For the mean change in hip BMD, there was a 4.5 increase from baseline with one year of alendronate compared to a 0.1 decrease after one year of placebo.
Povprečna sprememba BMD kolka je bila v primerjavi z izhodiščem 4,5% po enem letu prejemanja alendronata in 0,1% po enem letu prejemanja placeba.
For the medicine to work effectively, you or your child should take the tablets as instructed and should complete the 3 days course of treatment.
Za učinkovitost tega zdravila morate vi ali vaš otrok tablete jemati skladno z navodili in izpeljati 3-dnevni cikel zdravljenja.
For the metaphylaxis of BRD the effect of ZACTRAN was studied in comparison to placebo (dummy treatment) in cattle which had been in contact with diseased animals on the same farm and, therefore, likely also to develop the disease.
Učinkovitost zdravila ZACTRAN pri metafilaksi respiratorne bolezni govedi so proučevali tako, da so ga primerjali s placebom (zdravilom brez zdravilne učinkovine) pri govedu, ki je bilo v stiku z okuženimi živalmi na isti kmetiji in pri katerem posledično obstaja večja verjetnost, da zbolijo za to boleznijo.
For the mixed products the onset of immunity is 3 weeks and the duration of immunity is 6 weeks for the claimed protection against Massachusetts and variant strain 4-91 of IBV.
Za mešana cepiva se začne imunost po 3 tednih in traja 6 tednov za navedeno zaščito proti virusu Massachussets in proti variantnemu sevu kužnega bronhitisa perutnine (IBV) 4-91.
For the mixed products the onset of immunity is 3 weeks and the duration of immunity is 6 weeks for the claimed protection against Massachusetts and variant strain 4-91 of IBV.
Za mešana cepiva se začne imunost po 3 tednih in traja 6 tednov za zagotovljeno zaščito proti virusu Massachussets in proti variantnemu sevu kužnega bronhitisa perutnine (IBV) 4-91.
For the mixed products the onset of immunity is 3 weeks and the duration of immunity is 8 weeks for the claimed protection against Massachussets and QX-like strains of IBV.
Za mešana zdravila je začetek imunosti 3 tedne, trajanje imunosti pa 8 tednov za zagotovljeno zaščito proti sevu Masachussets in sevu podobnemu QX virusa kužnega bronhitisa.
For the mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation
Za izplavljanje matičnih celic v periferno kri pri zdravih darovalcih pred alogensko presaditvijo v periferno kri izplavljenih matičnih celic
For the mobilisation of PBPCs in patients undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation
Za mobilizacijo PBPCs, pri bolnikih, zdravljenih z mielosupresivno ali mieloablativno terapijo, ki ji sledi avtologna presaditev PBPC.
For the multi-dose nasal spray and multi-dose nasal spray DoseGuard all unused devices or empty containers should be returned systematically according to the local regulation.
Za večodmerno pršilo za nos in večodmerno pršilo za nos DoseGuard - vsa neuporabljena pršila ali prazne vsebnike je treba sistematično vračati v skladu z lokalnimi predpisi.
For the multi-dose nasal spray: information about the dose counting scheme.
Za večodmerno pršilo za nos: informacije o shemi štetja odmerkov.
For the next dose, push and hold the Dose Knob in and count to 5 slowly before removing the needle.
Pri naslednjem injiciranju pritisnite in držite gumb za odmerjanje ter preden potegnete ven iglo, počasi štejte do 5 .
For the next hour (60 minutes) after you’ve taken your tablet
Naslednjo uro (60 minut) po tem, ko ste vzeli tableto
For the next hour (60 minutes) after you’ve taken your tablet
Naslednjo uro (60 minut) potem, ko ste vzeli svojo tableto:
For the next injection patients can return to their chosen injection day.
Za naslednjo injekcijo se bolniki lahko vrnejo nazaj na izbrani dan za injiciranje.
For the next step hold the pen in the middle of the barrel.
Za naslednji korak držite peresnik na sredi telesa.
For the oral corticosteroid-sparing study MEA115575, a total of 135 patients were enrolled (55% were female; mean age of 50 years) who were being treated daily with OCS (5-35 mg per day), and high-dose ICS plus an additional maintenance medicine.
Študija varčevanja s peroralnim kortikosteroidom MEA115575 je zajela 135 bolnikov (55 % žensk, povprečna starost 50 let), ki so se zdravili s PKS (5-35 mg na dan) ter visokim odmerkom IKS in dodatnim vzdrževalnim zdravilom.
For the other patients the urine should be collected for at least 6 hours.
Pri ostalih bolnikih pa je potrebno zbirati urin vsaj šest (6) ur.
For the overall study population, pain intensity was statistically significantly lower for Ilaris 150 mg compared with triamcinolone acetonide at 72 hours.
V celotni populaciji je bila intenzivnost bolečine 72 ur po odmerjanju statistično značilno manjša po uporabi zdravila Ilaris 150 mg v primerjavi z uporabo triamcinolon acetonida.
For the participants completing the diary in each of these studies, statistically significant improvements at Week 12 from baseline compared to placebo in patient-reported signs and symptoms of itching, pain and scaling were demonstrated.
Po podatkih bolnikov, ki so izpolnjevali ta dnevnik, je v vsaki od obeh navedenih študij v 12 tednih prišlo do statistično značilno večjega izboljšanja od izhodišča glede znakov in simptomov srbenja, zadebelitve in luščenja kože, kot so jih opisovali bolniki, v primerjavi s tistimi, ki so prejemali placebo.
For the patients who achieved immune reconstitution, a non- relapse mortality (NRM) of 17% was reported, with 35% of these patients being disease free at 5 years and 34% alive at 10 years.
Pri bolnikih, ki so dosegli imunsko reaktivacijo, so poročali o smrtnosti brez ponovitve pri 17 %, pri čemer je bilo 35 % od teh bolnikov 5 let preživelo brez bolezni in 34 % pa jih je bilo po 10 letih živih.
For the patients who received placebo during the second year, the mean percent increase was 4.1 compared to baseline, but had decreased slightly compared to the end of 12 months of Preotact treatment.
Pri bolnicah, ki so drugo leto prejemale placebo, je bilo povprečno povečanje 4,1% glede na izhodišče, vendar se je nekoliko zmanjšalo, če primerjamo z zaključkom 12-mesečnega zdravljenja z zdravilom
For the PDT procedure, sedation may be required and consequently caution should be taken.
Za postopek s PDT je morda potrebna sedacija, zato je potrebna previdnost.
For the pooled crossover RA studies VI and VII, a statistically significant difference for injection site pain immediately after dosing was observed between Humira 40 mg/0.8 ml and Humira 40 mg/0.4 ml (mean VAS of 3.7 cm versus 1.2 cm, scale of 0-10 cm, P < 0.001).
V analizi združenih podatkov dveh navzkrižnih študij revmatoidnega artritisa VI in VII so na mestu injiciranja takoj po odmerjanju opazili statistično pomembno razliko med zdravilom Humira 40 mg/0,8 ml in zdravilom Humira 40 mg/0,4 ml (povprečen VAS 3,7 cm proti 1,2 cm, na lestvici 0-10 cm, P < 0,001).
For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.
Za preprečevanje in zdravljenje bruhanja v povezavi s Cerenia raztopino za injiciranje in v kombinaciji z ostalimi podpornimi terapijami.
For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures.
Za preprečevanje in zdravljenje bruhanja, v povezavi s Cerenia raztopino za injiciranje in v kombinaciji z ostalimi podpornimi terapijami.
For the prevention of atherothrombotic events in patients who have had acute coronary syndrome, Xarelto was compared with placebo (a dummy treatment) in one main study involving over 15,000 patients who had recently had an acute coronary syndrome.
Za preprečevanje aterotrombotičnih dogodkov pri bolnikih, ki so doživeli akutni koronarni sindrom, so zdravilo Xarelto primerjali s placebom (zdravilom brez zdravilne učinkovine) v eni glavni študiji, ki je vključevala 15 000 bolnikov, ki so nedavno doživeli akutni koronarni sindrom.
For the prevention of blood clot formation
Za preprečitev nastanka krvnih strdkov
For the prevention of delayed IRRs, oral corticosteroid (20 mg methylprednisolone or equivalent dose of a corticosteroid in accordance with local standards) should be administered on each of the two days following all infusions (beginning the day after the infusion).
Za preprečevanje poznih infuzijskih reakcij je treba bolnikom prvi in drugi dan po vsaki infuziji dati peroralni kortikosteroid (20 mg metilprednizolona ali enakovreden odmerek drugega kortikosteroida v skladu z lokalnimi standardi).
For the prevention of delayed IRRs, oral corticosteroids should be administered to all patients the first and second day after all infusions.
Za preprečevanje poznih infuzijskih reakcij je treba vsem bolnikom prvi in drugi dan po vsaki infuziji dati peroralni kortikosteroid.
For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active.
V sezoni razmnoževanja bolh je treba za preprečevanje infestacij z njimi zdravilo za uporabo v veterinarski medicini dajati v mesečnih intervalih, in sicer mesec dni pred bolšjo sezono.
For the prevention of flea infestations, the veterinary medicinal product should be administered to the animal at monthly intervals throughout the flea season, starting one month before fleas become active.
V sezoni razmnoževanja bolh je treba za preprečevanje infestacij z njimi zdravilo za uporabo v veterinarski medicini dajati v mesečnih presledkih, in sicer en mesec dni preden bolhe postanejo aktivne.
For the prevention of heartworm disease and the concurrent treatment and prevention of flea infestations, the veterinary medicinal product must be given at regular monthly intervals during the time of the year when mosquitoes and fleas are present.
Za preprečevanje filarioze ter sočasno zdravljenje in preprečevanje infestacij z bolhami je treba to zdravilo dajati v rednih mesečnih intervalih v tistem obdobju leta, ko so prisotni komarji in bolhe.
For the prevention of invasive fungal infections, Noxafil oral suspension is given at a dose of 200 mg (5 ml) three times a day.
Pri preprečevanju invazivnih glivičnih okužb se uporablja peroralna suspenzija zdravila Noxafil v odmerku 200 mg (5 ml) trikrat na dan.
For the prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), (only for dogs 8 weeks of age or older).
Preprečevanje slabosti povzročene s kemoterapijo ter zdravljenje in preprečevanje bruhanja (razen slabosti zaradi vožnje) (samo za pse, stare 8 tednov in več)
For the prevention of nausea induced by chemotherapy.
Za preprečevanje slabosti, povzročene s kemoterapijo.
For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
Za preprečevanje perioperativne nauzee in bruhanja ter pospešitev okrevanja po splošni anesteziji z uporabo agonista µ-opioidnih receptorjev, morfina.
for the prevention of spirocercosis (a worm infection affecting the gullet) in dogs
za preprečevanje spirocerkoze (okužbe z zajedavci, ki prizadene požiralnik) pri psih;
For the prevention of stroke and blood clots in patients with non-valvular atrial fibrillation, Pradaxa is taken as one 150 mg capsule twice a day and should be taken long term.
Pri preprečevanju kapi in krvnih strdkov pri bolnikih z atrijsko fibrilacijo, ki ni povezana s srčnimi zaklopkami, se zdravilo Pradaxa jemlje kot ena 150-miligramska kapsula dvakrat dnevno in se mora jemati dolgotrajno.
For the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, the recommended dose is 15 mg once daily (see section 5.2).
Za preprečevanje možganske kapi ali sistemske embolije pri bolnikih z nevalvularno atrijsko fibrilacijo je priporočeni odmerek 15 mg enkrat na dan (glejte poglavje 5.2).
for the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT and PE, apixaban should be used with caution;
pri preprečevanju možganske kapi ter sistemske embolije pri bolnikih z NVAF in preprečevanju ponovne GVT ter PE je treba apiksaban uporabljati previdno.
for the prevention of stroke and systemic embolism in patients with NVAF:
pri preprečevanju možganske kapi in sistemske embolije pri bolnikih z NVAF morajo:
For the prevention of stroke and systemic embolism, Xarelto was compared with warfarin (another medicine that prevents the blood from clotting) in one main study in 14,264 patients with non-valvular atrial fibrillation.
Za preprečevanje možganske kapi in sistemske embolije so v glavni študiji, v katero je bilo vključenih 14 264 bolnikov z atrijsko fibrilacijo brez okvare srčnih zaklopk, zdravilo Xarelto primerjali z varfarinom (drugim zdravilom za preprečevanje strjevanja krvi).
For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
Za preprečevanje bruhanja in zmanjšanje slabosti, razen slabosti zaradi vožnje.
For the prevention of vomiting except that induced by motion sickness.
Za preprečevanje bruhanja razen bruhanja, ki je posledica vožnje
For the prevention of vomiting except that induced by motion sickness.
Za preprečevanje bruhanja, razen bruhanja, ki je posledica slabosti zaradi vožnje.
For the prevention of vomiting induced by motion sickness.
Za preprečevanje bruhanja, ki je posledica slabosti zaradi vožnje.
For the prevention of VTE after surgery, Xarelto was compared with enoxaparin (another medicine that prevents the blood from clotting) in three main studies, two in patients undergoing hip replacement surgery and one in patients undergoing knee replacement surgery.
Zdravilo Xarelto so v okviru preprečevanja VTE po operaciji primerjali z učinkom enoksaparina (drugega zdravila za preprečevanje strjevanja krvi) v treh glavnih študijah, pri čemer sta dve potekali z bolniki po kirurški zamenjavi kolka in ena z bolniki po kirurški zamenjavi kolena.
For the prevention of VTE in elective hip or knee replacement surgery (VTEp), the treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTEt), apixaban is to be used with caution in patients with severe renal impairment (creatinine clearance 15-29 mL/min) (see sections 4.2 and 5.2).
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina 15-29 ml/min) je za preprečevanje VTE pri načrtovani kirurški zamenjavi kolka ali kolena (VTEp), zdravljenje GVT, zdravljenje PE ter preprečevanje ponovne GVT in PE (VTEt) treba apiksaban uporabljati previdno (glejte poglavji 4.2 in 5.2).